Journal article
The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
Abstract
OBJECTIVE: The sodium-glucose transporter 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin are recently approved medications for type 2 diabetes. Recent studies indicate that SGLT2 inhibitors may inhibit the growth of some cancer cells but the mechanism(s) remain unclear.
METHODS: Cellular proliferation and clonogenic survival were used to assess the sensitivity of prostate and lung cancer cell growth to the SGLT2 inhibitors. Oxygen …
Authors
Villani LA; Smith BK; Marcinko K; Ford RJ; Broadfield LA; Green AE; Houde VP; Muti P; Tsakiridis T; Steinberg GR
Journal
Molecular Metabolism, Vol. 5, No. 10, pp. 1048–1056
Publisher
Elsevier
Publication Date
10 2016
DOI
10.1016/j.molmet.2016.08.014
ISSN
2212-8778